ZimVie Shareholders Receive Final Payout as Company Goes Private

The publicly traded chapter of ZimVie has officially concluded. The company's equity ceased trading on the NASDAQ exchange effective October 20, 2025, marking the definitive end of its tenure as a publicly listed entity.

This departure from public markets followed a predetermined path. Investment firm ARCHIMED had previously disclosed in July 2025 its intention to acquire the company outright for $19 per share. The all-cash transaction, valued at approximately $730 million, successfully gained shareholder approval during a vote held on October 10. The deal was formally finalized just ten days later.

For investors, the acquisition price represented a significant premium compared to the stock's trading level before the takeover announcement. This outcome delivered a clear financial gain for shareholders who maintained their positions through the entire process.

Strategic Shift Preceded Final Transaction

The move into private ownership follows a period of strategic refocusing for the company. In a significant earlier development during April 2024, ZimVie divested its spinal implants business to H.I.G. Capital for $375 million. This maneuver streamlined the company's operations to concentrate exclusively on its dental implants division—precisely the business segment that ARCHIMED now aims to develop further.

Should investors sell immediately? Or is it worth buying ZimVie?

ARCHIMED, a healthcare-focused investment group managing assets worth around €8 billion, has assumed full strategic control. ZimVie now operates as a wholly-owned subsidiary, returning to the status of a private enterprise.

Investment Implications and Future Outlook

The consequence for the investment community is unambiguous: ZimVie shares no longer exist. The regular cycle of analyst ratings, quarterly earnings reports, and technical chart analysis is now a matter of historical record. The company's journey on the public markets is conclusively over.

ARCHIMED's strategy involves pursuing growth initiatives away from the scrutiny and reporting requirements of public markets. Market observers will be watching to see if the dental implant business can accelerate its innovation trajectory under this private ownership model. For former equity holders, however, the situation is resolved, with the $19 per share payment serving as the final transaction.